摘要
肠促胰素是由肠上皮内分泌细胞分泌的一类肠源性激素.已有大量研究去探索肠促胰素分泌的分子机制,包括葡萄糖、脂质、蛋白质等营养素对肠道内分泌细胞的促分泌作用.本文将对影响肠促胰素分泌的相关感应信号通路研究进展作一综述.
Incretin is a kind of intestinal hormone secreted by the enteroendocrine cells in the intestinal epithelium.There has been plenty of research to explore the molecular mechanisms of incretin hormone secretion,including secretionpromoting factors such as glucose,lipid,protein and other nutrients in enteroendocrine cells.This review aims to discuss the signal pathways related to incretin hormone secretion.
引文
1 Pannacdulli N,Le DS,Salbe AD,Chen K,Reiman EM,Tataranni PA,Krakoff J.Postprandial glucagon-like peptide-1(GLP-1)response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans.Neurointage2007;35:511-517[PMID:17317222 DOI:10.1016/j.neuroimage.2006.12.035]
2 Vilsboll T,Christensen M,Junker AE,Knop FK,Gluud LL.Effects of glucagon-like peptide-1receptor agonists on weight loss:systematic review and meta-analyses of randomised controlled trials.BMJ 2012;344:d7771[PMID:22236411 DOI:10.1136/bmj.d7771]
3 Baggio LL,Drucker DJ.Biology of incretins:GLP-1 and GIP.Gastroenterology 2007;132:2131-2157[PMID:17498508]
4 Koliaki C,Doupis J.Incretin-based therapy:a powerful and promising weapon in the treatment of type 2 diabetes mellitus.Diabetes Ther 2011;2:101-121[PMID:22127804 DOI:10.1007/sl3300-011-0002-3]
5 Buse JB,Nauck M,Forst T,Sheu WH,Shenouda SK,Heilmann CR,Hoogwerf BJ,Gao A,Boardman MK,Fineman M,Porter L,Schernthaner G.Exenatide once weekly versus liraglutide once daily in patients with type 2diabetes(DURATION-6):a randomised,openlabel study.Lancet 2013;381:117-124[PMID:23141817 DOI:10.1016/S0140-673]
6 Nauck MA,Vardarli I,Deacon CF,Hoist JJ,Meier JJ.Secretion of glucagon-like peptide-1(GLP-1)in type 2 diabetes:what is up,what is down?Diabetologia 2011;54:10-18[PMID:20871975 DOI:10.1007/S00125-010-1896-4]
7 Reimann F.Molecular mechanisms underlying nutrient detection by incretin-secreting cells,lnt Dairy J 2010;20:236-242[PMID:20204054]
8 Reimer RA.Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion,in the human NCI-H716 enteroendocrine cell line,is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases.J Endocrinol 2006;191:159-170[PMID:17065399]
9 Ezcurra M,Reimann F,Gribble FM,Emery E.Molecular mechanisms of incretin hormone secretion.Curr Opin Pharmacol 2013;13:922-927[PMID:24035446 DOI:10.1016/j.coph.2013.08.013]
10 Parker HE,Reimann F,Gribble FM.Molecular mechanisms underlying nutrient-stimulated incretin secretion.Expert Rev Mol Med 2010;12:el[PMID:20047700 DOI:10.1017/S146239940900132X]
11 Egerod KL,Engelstoft MS,Grunddal KV,Nohr MK,Secher A,Sakata I,Pedersen J,Windelov JA,Ftichtbauer EM,Olsen J,Sundler F,Christensen JP,Wierup N,Olsen JV,Hoist JJ,Zigman JM,Poulsen SS,Schwartz TW.A major lineage of enteroendocrine cells coexpress CCK,secretin,GIP,GLP-1,PYY,and neurotensin but not somatostatin.Endocrinology 2012;153:5782-5795[PMID:23064014 DOI:10.1210/en.2012-1595]
12 Sleeth ML,Thompson EL,Ford HE,ZacVarghese SE,Frost G.Free fatty acid receptor 2and nutrient sensing:a proposed role for fibre,fermentable carbohydrates and short-chain fatty acids in appetite regulation.Nutr Res Rev 2010;23:135-145[PMID:20482937 DOI:10.1017/S0954422410000089]
13 Reimann F,Habib AM,Tolhurst G,Parker HE,Rogers GJ,Gribble FM.Glucose sensing in L cells:a primary cell study.Cell Metab 2008;8:532-539[PMID:19041768 DOI:10.1016/j.cmet.2008.11.002]
14 Bhartia M,Tahrani AA,Barnett AH.SGLT-2inhibitors in development for type 2 diabetes treatment.Rev Diabet Stud 2011;8:348-354[PMID:22262072 DOI:10.1900/RDS.2011.8.348]
15 Rosenwasser RF,Sultan S,Sutton D,Choksi R,Epstein BJ.SGLT-2 inhibitors and their potential in the treatment of diabetes.Diabetes Metab Syndr Obes 2013;6:453-467[PMID:24348059 DOI:10.2147/DMSO.S34416]
16 Basile J.A new approach to glucose control in type 2 diabetes:the role of kidney sodiumglucose co-transporter 2 inhibition.Postgrad Med2011;123:38-45[PMID:21680987 DOI:10.3810/pgm.2011.07.2302]
17 Gribble FM,Williams L,Simpson AK,Reimann F.A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line.Diabetes 2003;52:1147-1154[PMID:12716745]
18 Parker HE,Adriaenssens A,Rogers G,Richards P,Koepsell H,Reimann F,Gribble FM.Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion.Diabetologia2012;55:2445-2455[PMID:22638549 DOI:10.1007/s00125-012-2585-2]
19 Gorboulev V,Schtirmann A,Vallon V,Kipp H,Jaschke A,Klessen D,Friedrich A,Scherneck S,Rieg T,Cunard R,Veyhl-Wichmann M,Srinivasan A,Balen D,Breljak D,Rexhepaj R,Parker HE,Gribble FM,Reimann F,Lang F,Wiese S,Sabolic I,Sendtner M,Koepsell H.Na(+)-D-glucose cotransporter SGLTl is pivotal for intestinal glucose absorption and glucosedependent incretin secretion.Diabetes 2012;61:187-196[PMID:22124465 DOI:10.2337/db11-1029]
20 Powell DR,Smith M,Greer J,Harris A,Zhao S,DaCosta C,Mseeh F,Shadoan MK,Sands A,Zambrowicz B,Ding ZM.LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1(SGLT1)-mediated absorption of intestinal glucose.J Pharmacol Exp Ther 2013;345:250-259[PMID:23487174 DOI:10.1124/jpet.ll3.203364]
21 Powell DR,DaCosta CM,Gay J,Ding ZM,Smith M,Greer J,Doree D,Jeter-Jones S,Mseeh F,Rodriguez LA,Harris A,Buhring L,Platt KA,Vogel P,Brommage R,Shadoan MK,Sands AT,Zambrowicz B.Improved glycemic control in mice lacking Sglt1 and Sglt2.Am J Physiol Endocrinol Metab 2013;304:E117-E130[PMID:23149623 DOI:10.1152/ajpendo.00439.2012]
22 Stephens JW,Bodvarsdottir TB,Wareham K,Prior SL,Bracken RM,Lowe GD,Rumley A,Dunseath G,Luzio S,Deacon CF,Hoist JJ,Bain SC.Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.Diabetes Res Clin Pract2011;94:199-206[PMID:21835486 DOI:10.1016/j.diabres.2011.07.014]
23 Laffitte A,Neiers F,Briand L.Functional roles of the sweet taste receptor in oral and extraoral tissues.Curr Opin Clin Nutr Metab Care 2014;17:379-385[PMID:24763065 DOI:10.1097/MCO.0000000000000058]
24 Kyriazis GA,Smith KR,Tyrberg B,Hussain T,Pratley RE.Sweet taste receptors regulate basal insulin secretion and contribute to compensatory insulin hypersecretion during the development of diabetes in male mice.Endocrinology 2014;155:2112-2121[PMID:24712876 DOI:10.1210/en.2013-2015]
25 Young RL,Chia B,Isaacs NJ,Ma J,Khoo J,Wu T,Horowitz M,Rayner CK.Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes.Diabetes2013;62:3532-3541[PMID:23761104 DOI:10.2337/dbl3-0581]
26 Fujita Y,Wideman RD,Speck M,Asadi A,King DS,Webber TD,Haneda M,Kieffer TJ.Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo.Am J Physiol Endocrinol Metab 2009;296:E473-E479[PMID:19106249 DOI:10.1152/ajpendo.90636.2008]
27 Ma J,Bellon M,Wishart JM,Young R,Blackshaw LA,Jones KL,Horowitz M,Rayner CK.Effect of the artificial sweetener,sucralose,on gastric emptying and incretin hormone release in healthy subjects.Am J Physiol Gastrointest Liver Physiol 2009;296:G735-G739[PMID:19221011 DOI:10.1152/ajpgi.90708.2008]
28 Duca FA,Sakar Y,Covasa M.The modulatory role of high fat feeding on gastrointestinal signals in obesity.J Nutr Biochem 2013;24:1663-1677[PMID:24041374 DOI:10.1016/j.jnutbio.2013.05.005]
29 Hara T,Hirasawa A,Ichimura A,Kimura I,Tsujimoto G.Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders.J Pharnt Sci 2011;100:3594-3601[PMID:21618241 DOI:10.1002/jps.22639]
30 Shah BP,Liu P,Yu T,Hansen DR,Gilbertson TA.TRPM5 is critical for linoleic acid-induced CCK secretion from the enteroendocrine cell line,STC-1.Am J Physiol Cell Physiol 2012;302:C210-C219[PMID:21998136 DOI:10.1152/ajpcell.00209.2011]
31 Everard A,Lazarevic V,Derrien M,Girard M,Muccioli GG,Neyrinck AM,Possemiers S,Van Holle A,Francois P,de Vos WM,Delzenne NM,Schrenzel J,Cani PD.Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice.Diabetes 2011;60:2775-2786[PMID:21933985DOI:10.2337/db11-0227]
32 Reimann F,Tolhurst G,Gribble FM.G-proteincoupled receptors in intestinal chemosensation.Cell Metab 2012;15:421-431[PMID:22482725 DOI:10.1016/j.cmet.2011.12.019]
33 Tolhurst G,Heffron H,Lam YS,Parker HE,Habib AM,Diakogiannaki E,Cameron J,Grosse J,Reimann F,Gribble FM.Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.Diabetes2012;61:364-371[PMID:22190648 DOI:10.2337/db11-1019]
34 Reimann F,Williams L,da Silva Xavier G,Rutter GA,Gribble FM.Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells.Diabetologia 2004;47:1592-1601[PMID:15365617]
35 Tolhurst G,Zheng Y,Parker HE,Habib AM,Reimann F,Gribble FM.Glutamine triggers and potentiates glucagon-like peptide-1 secretion by raising cytosolic Ca2+and cAMP.Endocrinology2011;152:405-413[PMID:21209017 DOI:10.1210/en.2010-0956]
36 Greenfield JR,Farooqi IS,Keogh JM,Henning E,Habib AM,Blackwood A,Reimann F,Hoist JJ,Gribble FM.Oral glutamine increases circulating glucagon-like peptide 1,glucagon,and insulin concentrations in lean,obese,and type 2 diabetic subjects.Am J Clin Nutr 2009;89:106-113[PMID:19056578 DOI:10.3945/ajcn.2008.26362]
37 Samuel BS,Shaito A,Motoike T,Rey FE,Backhed F,Manchester JK,Hammer RE,Williams SC,Crowley J,Yanagisawa M,Gordon JI,Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G proteincoupled receptor,Gpr41.Proc Natl Acad Sci USA2008;105:16767-16772[PMID:18931303 DOI:10.1073/pnas.0808567105]
38 Flock GB,Cao X,Maziarz M,Drucker DJ.Activation of enteroendocrine membrane progesterone receptors promotes incretin secretion and improves glucose tolerance in mice.Diabetes2013;62:283-290[PMID:22933106 DOI:10.2337/db12-0601]
39 Parker HE,Wallis K,le Roux CW,Wong KY,Reimann F,Gribble FM.Molecular mechanisms underlying bile acid-stimulated glucagonlike peptide-1 secretion.Br J Pharmacol 2012;165:414-423[PMID:21718300 DOI:10.1111/j.1476-5381.2011.01561.x]
40 Wu T,Bound MJ,Standfield SD,Jones KL,Horowitz M,Rayner CK.Effects of taurocholic acid on glycemic,glucagon-like peptide-1,and insulin responses to small intestinal glucose infusion in healthy humans.J Clin Endocrinol Metab 2013;98:E718-E722[PMID:23418316 DOI:10.1210/jc.2012-3961]
41 Patti ME,Houten SM,Bianco AC,Bernier R,Larsen PR,Hoist JJ,Badman MK,Maratos-Flier E,Mun EC,Pihlajamaki J,Auwerx J,Goldfine AB.Serum bile acids are higher in humans with prior gastric bypass:potential contribution to improved glucose and lipid metabolism.Obesity(Silver Spring)2009;17:1671-1677[PMID:19360006 DOI:10.1038/oby.2009.102]
42 Chisholm C,Greenberg GR.Somatostatin-28regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures.Am J Physiol Endocrinol Metab 2002;283:E311-E317[PMID:12110536]
43 Moss CE,Marsh WJ,Parker HE,OgunnowoBada E,Riches CH,Habib AM,Evans ML,Gribble FM,Reimann F.Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents.Diabetologia 2012;55:3094-3103[PMID:22872212 DOI:10.1007/S00125-012-2663-5]
44 Woerle HJ,Carneiro L,Derani A,Goke B,Schirra J.The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Diabetes 2012;61:2349-2358[PMID:22721966 DOI:10.2337/db11-1701]
45 Gejl M,Sondergaard HM,Stecher C,Bibby BM,Moller N,Botker HE,Hansen SB,Gjedde A,Rungby J,Brock B.Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.J Clin Endocrinol Metab 2012;97:E1165-E1169[PMID:22544917 DOI:10.1210/jc.2011-3456]
46 Habib AM,Richards P,Rogers GJ,Reimann F,Gribble FM.Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells.Diabetologia 2013;56:1413-1416[PMID:23519462 DOI:10.1007/s00125-013-2887-z]
47 Katz LB,Gambale JJ,Rothenberg PL,Vanapalli SR,Vaccaro N,Xi L,Sarich TC,Stein PP.Effects of JNT-38431055,a novel GPR119 receptor agonist,in randomized,double-blind,placebo-controlled studies in subjects with type 2 diabetes.Diabetes Obes Metab 2012;14:709-716[PMID:22340428 DOI:10.1111/j.1463-1326.2012.01587.x]
48 Araki T,Hirayama M,Hiroi S,Kaku K.GPR40-induced insulin secretion by the novel agonist TAK-875:first clinical findings in patients with type 2 diabetes.Diabetes Obes Metab 2012;14:271-278[PMID:22051148 DOI:10.1111/j.1463-1326.2011.01525.x]
49 Zambrowicz B,Freiman J,Brown PM,Frazier KS,Turnage A,Bronner J,Ruff D,Shadoan M,Banks P,Mseeh F,Rawlins DB,Goodwin NC,Mabon R,Harrison BA,Wilson A,Sands A,Powell DR.LX4211,a dual SGLT1/SGLT2 inhibitor,improved glycemic control in patients with type 2 diabetes in a randomized,placebo-controlled trial.Clin Pharmacol Ther 2012;92:158-169[PMID:22739142DOI:10.1038/dpt.2012.58]
50 Jimenez A,Casamitjana R,Flores L,Viaplana J,Corcelles R,Lacy A,Vidal J.Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects.Ann Surg 2012;256:1023-1029[PMID:22968072 DOI:10.1097/SLA.0b013e318262ee6b]
